Analyst Price Targets — KRRO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 13, 2026 11:27 am | Steve Seehouse | Cantor Fitzgerald | $22.00 | $11.50 | StreetInsider | Korro Bio (KRRO) PT Raised to $22 at Cantor Fitzgerald on UCD Potential |
| March 13, 2026 8:26 am | Ryan Deschner | Raymond James | $23.00 | $11.50 | StreetInsider | Raymond James Upgrades Korro Bio Inc. (KRRO) to Outperform |
| February 18, 2026 9:23 pm | — | Raymond James | $18.00 | $11.24 | StreetInsider | Clear Street Upgrades Korro Bio Inc. (KRRO) to Buy |
| January 29, 2026 11:08 am | — | H.C. Wainwright | $20.00 | $11.69 | TheFly | Korro Bio upgraded to Buy from Neutral at H.C. Wainwright |
| January 29, 2026 9:58 am | — | Chardan Capital | $15.00 | $11.69 | TheFly | Korro Bio upgraded to Buy from Neutral at Chardan |
| January 28, 2026 11:12 pm | Yasmeen Rahimi | Piper Sandler | $30.00 | $11.69 | TheFly | Korro Bio upgraded to Overweight from Neutral at Piper Sandler |
| January 28, 2026 12:09 pm | Myles Minter | William Blair | $10.00 | $11.17 | StreetInsider | William Blair Reiterates Market Perform Rating on Korro Bio Inc. (KRRO), 'early stages of its pipeline with clinical data unlikely until 2027' |
| January 28, 2026 11:54 am | — | Oppenheimer | $22.00 | $10.74 | TheFly | Korro Bio upgraded to Outperform from Perform at Oppenheimer |
| January 27, 2026 9:10 pm | Steve Seedhouse | Cantor Fitzgerald | $21.00 | $10.74 | TheFly | Korro Bio upgraded to Overweight from Neutral at Cantor Fitzgerald |
| April 16, 2025 8:24 am | Keay Nakae | Chardan Capital | $25.00 | $13.46 | TheFly | Korro Bio initiated with a Buy at Chardan |
Latest News for KRRO
Korro Bio reported a net loss of $117.3 million for the year ended December 31, 2025, compared to a loss of $83.6 million in the previous year, driven by non-cash impairment charges.
Korro Bio, Inc. (KRRO) came out with a quarterly loss of $5.32 per share versus the Zacks Consensus Estimate of a loss of $1.93. This compares to a loss of $2.26 per share a year ago.
Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy Advanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency; on track to nominate development candidate second quarter of 2026 Recent oversubscribed $85 million private placement extends cash runway into the second half of 2028 CAMBRIDGE, Mass.,…
CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced it has entered into a subscription agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $85 million…
Shares of Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) have received an average rating of "Hold" from the eleven analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, three have given a buy recommendation and one has issued
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KRRO.
U.S. House Trading
No House trades found for KRRO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.